Netherlands‑based medical robotics company Vitestro closed a $70 million Series B to commercialize its Aletta Autonomous Robotic Phlebotomy Device (ARPD) and expand clinical pilots across Europe and the U.S. The company said proceeds will fund technical refinement, clinical studies, manufacturing scale‑up and a US De Novo regulatory pathway. Vitestro positions Aletta to address high‑volume venous access bottlenecks by combining multimodal imaging, advanced robotics and AI to autonomously locate veins and collect blood. The firm highlighted clinical validation and integration targets for outpatient workflows and laboratory automation. Investors backing the round cited the procedure’s high volume and operational strain as drivers for adoption. The financing advances regulatory and commercialization work that will determine the device’s ability to penetrate phlebotomy and diagnostic services markets.